Last reviewed · How we verify
NCT05282745
A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
trial testing Follow-up in HPV Infection in 4,000 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Fujian Maternity and Child Health Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 4,000 |
| Start date | 15 December 2021 |
| Primary completion | 30 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 10 locations across China |
Drugs / interventions tested
- Follow-up
Conditions studied
- HPV Infection — all drugs for HPV Infection →
- HSIL, High-Grade Squamous Intraepithelial Lesions — all drugs for HSIL, High-Grade Squamous Intraepithelial Lesions →
- Viral Load — all drugs for Viral Load →
Sponsor
Fujian Maternity and Child Health Hospital
Who can join
20 and older, female only, with HPV Infection or HSIL, High-Grade Squamous Intraepithelial Lesions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Human papillomavirus (HPV) infection has become one of the most important health problems faced by women all over the world. A large number of studies have shown that women's cervical, vaginal and perianal precancerous lesions, related cancers, condyloma acuminatum and other sexually transmitted diseases (STD) are closely related to HPV infection. Among them, the persistent infection of high-risk human papillomavirus (HR-HPV) is closely related to the occurrence of invasive cervical cancer. Previous studies have shown that there are significant differences in the effects of multiple HPV infection and persistent infection of different types (such as type-16, -18, -39 and -52) on different levels of cervical lesions, and there is a certain correlation between HPV load in the process of persistent infection and the degree of cervical lesions. In addition, other studies have shown that HPV-16 viral load has certain clinical significance in predicting Cin2 / CIN3 high-grade cervical lesions, and HPV viral load level is significantly different in cervical low-grade squamous intraepithelial lesion (LSIL) and cervical high-grade squamous intraepithelial lesion (HSIL). The above biological changes such as HPV infection type, quantity and proportion can promote the occurrence and development of cervical precancerous lesions and related cancers to varying degrees. It can be seen that the study of the relationship between HPV viral load and cervical lesions is of great significance for clinical disease development prediction and cervical cancer screening.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05282745
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Follow-up
Trials testing the same drug.
- NCT06743282 — Senyo Health With Substance Use Disorder (SUD) in Primary Care · NA · enrolling by invitation
- NCT07007377 — Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients · recruiting
- NCT06866483 — Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-m · recruiting
- NCT06651203 — Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Dise · not yet recruiting
- NCT06381284 — Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients · completed
Other recruiting trials for HPV Infection
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
- NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting
Other Fujian Maternity and Child Health Hospital trials
Trials by the same sponsor.
- NCT06276309 — Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors · recruiting
- NCT06137352 — Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity · not yet recruiting
- NCT06204133 — Model Study on Cervical Cancer Screening Strategies and Risk Prediction · completed
- NCT05932563 — Study on the Epidemiological Characteristics of Female HPV Vaccination in China · unknown
- NCT05745597 — Prognostic Study of HPV Virus Integration in Women With HSIL · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05282745 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Maternity and Child Health Hospital
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05282745.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing